MCID: MSC072
MIFTS: 53

Muscle Cancer

Categories: Cancer diseases, Muscle diseases

Aliases & Classifications for Muscle Cancer

MalaCards integrated aliases for Muscle Cancer:

Name: Muscle Cancer 12 55 15
Myosarcoma 12 55 44 73
Malignant Neoplasm of Muscle 12 73
Malignant Tumor of the Muscle 12
Malignant Tumor of Muscle 12
Myomatous Neoplasm 73
Muscle Neoplasms 44

Classifications:



External Ids:

Disease Ontology 12 DOID:4045
ICD10 33 C49
NCIt 50 C4883
SNOMED-CT 68 20667008 93913006

Summaries for Muscle Cancer

Disease Ontology : 12 A musculoskeletal system cancer that is located in muscle.

MalaCards based summary : Muscle Cancer, also known as myosarcoma, is related to skeletal muscle cancer and leiomyosarcoma, and has symptoms including muscle weakness, myoclonus and myalgia. An important gene associated with Muscle Cancer is PAX3 (Paired Box 3), and among its related pathways/superpathways are Endometrial cancer and ErbB signaling pathway. The drugs Doxorubicin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and prostate, and related phenotypes are cellular and growth/size/body region

Wikipedia : 76 A soft-tissue sarcoma is a form of sarcoma that develops in connective tissue, though the term is... more...

Related Diseases for Muscle Cancer

Diseases related to Muscle Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 171)
# Related Disease Score Top Affiliating Genes
1 skeletal muscle cancer 32.6 ASPSCR1 FOXO1 KIDINS220 MB MYOD1 MYOG
2 leiomyosarcoma 30.7 DES KIT MB MDM2 MYOG PGR
3 rhabdomyosarcoma 30.5 DES EWSR1 FOXO1 MB MDM2 MYOD1
4 botryoid rhabdomyosarcoma 30.3 DES MB MYOD1 PAX3
5 leiomyoma 30.0 CD34 DES KIT PGR
6 sarcoma 29.6 ASPSCR1 CREB3L2 EWSR1 KIT MDM2 TFE3
7 myoma 11.5
8 mixed endometrial stromal and smooth muscle tumor 11.0
9 uterus leiomyosarcoma 10.8
10 striated muscle rhabdoid tumor 10.7
11 epulis 10.3 DES PGR
12 lymphangiomatosis 10.3 DES PGR
13 lung leiomyoma 10.3 MB PGR
14 endometrium carcinoma in situ 10.3 PGR TP53
15 ovarian fibrothecoma 10.3 DES KIT
16 prostate embryonal rhabdomyosarcoma 10.3 KIT MYOD1
17 giant cell myocarditis 10.3 DES MB
18 orbit rhabdomyosarcoma 10.3 MB MYOG
19 malignant ectomesenchymoma 10.3 DES FOXO1
20 ectomesenchymoma 10.3 DES FOXO1
21 testicular gonadoblastoma 10.3 KIT WT1
22 malignant triton tumor 10.3 DES MB MYOD1
23 spindle cell rhabdomyosarcoma 10.3 DES MB MYOD1
24 perivascular epithelioid cell tumor 10.3 DES KIT PGR
25 vulvar benign neoplasm 10.3 CALD1 PGR
26 vulvar leiomyoma 10.3 CALD1 PGR
27 smooth muscle tumor 10.3 DES KIT PGR
28 pleomorphic lipoma 10.3 MDM2 PGR
29 cerebellar angioblastoma 10.3 TP53 WT1
30 angiomyolipoma 10.2 DES KIT PGR
31 ring chromosome 7 10.2 MDM2 TP53
32 zika virus infection 10.2 MDM2 TP53
33 breast malignant phyllodes tumor 10.2 PGR TP53
34 prostate stromal sarcoma 10.2 CD34 PGR
35 kidney sarcoma 10.2 MB WT1
36 spindle cell lipoma 10.2 DES FOXO1 MDM2
37 endosalpingiosis 10.2 PGR WT1
38 esophagus sarcoma 10.2 CREB3L2 KIT
39 prostate rhabdomyosarcoma 10.2 KIT MYOD1
40 central nervous system mesenchymal non-meningothelial tumor 10.2 FOXO1 MYOD1 PAX3 PAX7
41 gallbladder leiomyoma 10.2 CD34 KIT
42 lung leiomyosarcoma 10.2 CD34 KIT
43 trigonitis 10.2 CD34 PGR
44 lung meningioma 10.2 CD34 PGR
45 lung combined type small cell carcinoma 10.2 CALD1 MYOG
46 malignant fibroxanthoma 10.2 DES MDM2 MYOD1
47 liver leiomyoma 10.2 CD34 KIT
48 vulvar dystrophy 10.2 CD34 PGR
49 female reproductive endometrioid cancer 10.2 PGR TP53 WT1
50 actinic cheilitis 10.2 MDM2 TP53

Graphical network of the top 20 diseases related to Muscle Cancer:



Diseases related to Muscle Cancer

Symptoms & Phenotypes for Muscle Cancer

UMLS symptoms related to Muscle Cancer:


muscle weakness, myoclonus, myalgia, torticollis, muscle rigidity, muscle cramp, muscle spasticity

MGI Mouse Phenotypes related to Muscle Cancer:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.35 CD34 DES FOXO1 KIDINS220 KIT MB
2 growth/size/body region MP:0005378 10.34 CREB3L2 FOXO1 KIDINS220 KIT MB MDM2
3 cardiovascular system MP:0005385 10.32 DES FOXO1 KIDINS220 KIT MB MDM2
4 homeostasis/metabolism MP:0005376 10.31 CD34 DES FOXO1 KIT MB MDM2
5 mortality/aging MP:0010768 10.31 CREB3L2 DES FOXO1 KIDINS220 KIT MB
6 hematopoietic system MP:0005397 10.29 CD34 FOXO1 KIT MB MDM2 PAX3
7 embryo MP:0005380 10.24 FOXO1 KIT MB MDM2 MYOG PAX3
8 muscle MP:0005369 10.18 DES FOXO1 KIT MB MDM2 MYOD1
9 craniofacial MP:0005382 10.16 CREB3L2 FOXO1 KIT MDM2 PAX3 PAX7
10 integument MP:0010771 10.13 CD34 FOXO1 KIT MDM2 MYOG PAX3
11 digestive/alimentary MP:0005381 10.09 CREB3L2 FOXO1 KIT MDM2 PAX3 PAX7
12 neoplasm MP:0002006 10.07 CD34 FOXO1 KIT MDM2 MYOD1 PAX3
13 no phenotypic analysis MP:0003012 10.06 FOXO1 KIDINS220 KIT MDM2 MYOD1 MYOG
14 limbs/digits/tail MP:0005371 10 CREB3L2 FOXO1 KIT MDM2 PAX3 PGR
15 normal MP:0002873 10 FOXO1 KIT MDM2 MYOD1 MYOG PAX3
16 respiratory system MP:0005388 9.56 KIT MB MYOD1 MYOG PAX3 PAX7
17 pigmentation MP:0001186 9.55 KIT MDM2 PAX3 TFE3 TP53
18 skeleton MP:0005390 9.36 CREB3L2 FOXO1 KIT MDM2 MYOD1 MYOG

Drugs & Therapeutics for Muscle Cancer

Drugs for Muscle Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 211)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 6055-19-2, 50-18-0 2907
3
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
4 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
5 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
6 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
7 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
8 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
10 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
13
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 123948-87-8, 119413-54-6 60700
14
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
15
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
16
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
17
Vincristine Approved, Investigational Phase 3,Phase 2 57-22-7, 2068-78-2 5978
18
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 60780 44424639
19
Morphine Approved, Investigational Phase 3,Phase 1,Phase 2 57-27-2 5288826
20
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
21
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
22
Mesna Approved, Investigational Phase 3,Phase 2,Not Applicable 3375-50-6 598
23
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
24
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
25
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
26
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
27
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
28
Idarubicin Approved Phase 3 58957-92-9 42890
29
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
30 Trofosfamide Investigational Phase 3 22089-22-1
31
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
32 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
33 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
34 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
35 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
36 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
37 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
38 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1,Not Applicable
39 Antifungal Agents Phase 3,Phase 2,Phase 1
40 Bone Density Conservation Agents Phase 3,Phase 1
41 Calcium, Dietary Phase 3
42
Fludarabine Approved Phase 1, Phase 2,Phase 2 75607-67-9, 21679-14-1 30751
43
Vinblastine Approved Phase 2 865-21-4 241903 13342
44
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
45
Melphalan Approved Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
46
Bevacizumab Approved, Investigational Phase 2 216974-75-3
47
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
48
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
49
Dasatinib Approved, Investigational Phase 2,Phase 1 302962-49-8 3062316
50
Paclitaxel Approved, Vet_approved Phase 1, Phase 2,Phase 2,Not Applicable 33069-62-4 36314

Interventional clinical trials:

(show top 50) (show all 167)
# Name Status NCT ID Phase Drugs
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
2 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
3 High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma Unknown status NCT00354744 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
4 Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Unknown status NCT00075582 Phase 3 dactinomycin;cyclophosphamide;vincristine sulfate
5 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00002995 Phase 3 cyclophosphamide;vincristine sulfate
6 Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00354835 Phase 3 Irinotecan Hydrochloride;Cyclophosphamide;Vincristine Sulfate
7 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
8 Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma Completed NCT00003958 Phase 3 vincristine sulfate;cyclophosphamide;topotecan hydrochloride
9 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
10 Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma Recruiting NCT00876031 Phase 3 trofosfamide, idarubicin, etoposide
11 Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma Recruiting NCT02567435 Phase 3 Cyclophosphamide;Irinotecan Hydrochloride;Temsirolimus;Vincristine Sulfate;Vinorelbine
12 Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood Terminated NCT00162695 Phase 3 Ifosfamide, oncovin, actinomycine D, epirubicine, carboplatinum, etoposide
13 Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas Unknown status NCT01216839 Phase 2 Everolimus
14 Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal Rhabdomyosarcoma Unknown status NCT00245141 Phase 2 cyclophosphamide;vincristine sulfate
15 Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma Unknown status NCT00245089 Phase 2 cyclophosphamide;vincristine sulfate
16 Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas Unknown status NCT02409576 Phase 1, Phase 2
17 Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse Unknown status NCT00180947 Phase 2 Vinorelbine, cyclofosfamide
18 Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg Completed NCT00019968 Phase 2 melphalan;tumor necrosis factor
19 Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Completed NCT01222715 Phase 2 Cyclophosphamide;Temsirolimus;Vinorelbine Tartrate
20 Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma Completed NCT01055314 Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Irinotecan Hydrochloride;Temozolomide;Vincristine Sulfate Liposome
21 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma Completed NCT00003955 Phase 2 cyclophosphamide;irinotecan hydrochloride;vincristine sulfate
22 Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma Completed NCT00055939 Phase 2 exatecan mesylate
23 Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma Completed NCT00025363 Phase 2 vincristine sulfate;irinotecan hydrochloride;cyclophosphamide;doxorubicin hydrochloride;ifosfamide;etoposide;tirapazamine
24 Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
25 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
26 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma Completed NCT00668148 Phase 2
27 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
28 Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Completed NCT01962103 Phase 1, Phase 2 nab-paclitaxel;nab-paclitaxel
29 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
30 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2 sorafenib tosylate
31 NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) Completed NCT01386619 Phase 1, Phase 2
32 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01154816 Phase 2 Alisertib
33 A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB Completed NCT01125800 Phase 1, Phase 2 LDE225
34 Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma Completed NCT00923351 Phase 1, Phase 2 Tumor Purged/CD25 Depleted Lymphocytes;rhIL-7
35 Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors Completed NCT00070109 Phase 2 trabectedin
36 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
37 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
38 A Study of Pemetrexed in Children With Recurrent Cancer Completed NCT00520936 Phase 2 pemetrexed
39 A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas Completed NCT00001566 Phase 2 indinavir sulfate
40 A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas Completed NCT00001564 Phase 2 EF-1 Peptide;EF-2 Peptide;PXFK Peptide;E7 Peptide;IL-2;IL-4;GM-CSF;CD40 Ligand
41 Ixabepilone in Treating Young Patients With Refractory Solid Tumors Completed NCT00331643 Phase 2 ixabepilone
42 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
43 Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant Completed NCT00309907 Phase 2 methylprednisolone
44 Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy Completed NCT00187109 Phase 1, Phase 2 Recombinant Human Thrombopoietin
45 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
46 Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone Completed NCT00006234 Phase 1, Phase 2
47 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
48 New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma Completed NCT00001335 Phase 2 ADR-529;Topotecan;G-CSF
49 Hypofractionated Radiotherapy With Sequential Chemotherapy in Primary Unresectable or Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Recruiting NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
50 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Recruiting NCT01883518 Phase 1, Phase 2

Search NIH Clinical Center for Muscle Cancer

Cochrane evidence based reviews: myosarcoma

Genetic Tests for Muscle Cancer

Anatomical Context for Muscle Cancer

MalaCards organs/tissues related to Muscle Cancer:

41
Liver, Lung, Prostate, Kidney, Bone, Smooth Muscle, Small Intestine

The Foundational Model of Anatomy Ontology organs/tissues related to Muscle Cancer:

19
Muscle

Publications for Muscle Cancer

Articles related to Muscle Cancer:

(show all 37)
# Title Authors Year
1
Cytotoxicity Studies of the Extracts, Fractions, and Isolated Compound of Pseudocedrela kotschyi on Cervical Cancer (HeLa), Breast Cancer (MCF-7) and Skeletal Muscle Cancer (RD) Cells. ( 28250653 )
2017
2
YAPping about differentiation therapy in muscle cancer. ( 25117705 )
2014
3
The not-so-skinny on muscle cancer. ( 23079652 )
2012
4
Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. ( 20193046 )
2010
5
A new model for muscle cancer. ( 17585343 )
2007
6
Cytotoxic effects of some animal and vegetable extracts and some chemicals on liver and colon carcinoma and myosarcoma. ( 14968209 )
2004
7
Ultrasound appearance of extratesticular myosarcoma. ( 1847943 )
1991
8
Radio-immunodetection of myosarcoma using 111indium antimyosin. ( 2168500 )
1990
9
Continuous internalization of tumor necrosis factor receptors in a human myosarcoma cell line. ( 2839482 )
1988
10
Budd Chiari syndrome from myosarcoma of right atrium. ( 512745 )
1979
11
Embryonal rhabdo-myosarcoma of middle ear: report of a case with 12 years' survival with a review of the literature. ( 4636807 )
1972
12
A case of circumscribed myosarcoma of the prostate. ( 4186113 )
1969
13
Radiological notes. Recurrent small bowel myosarcoma. ( 5237832 )
1968
14
Primary mixed myosarcoma of the uterine tube: a case report and review of the literature. ( 5635718 )
1968
15
Chemotherapy of myosarcoma (leio- and rhabdomyosarcoma). ( 5760796 )
1968
16
MYOSARCOMA OF THE UTERUS; A CLINICOPATHOLOGICAL STUDY. ( 14278890 )
1965
17
MYOSARCOMA OF THE BLADDER: REPORT OF TWO CASES. ( 14139618 )
1964
18
Myosarcoma of the jejunum. Report of a case. ( 14438488 )
1959
19
Pelvic exenteration for polypoid myosarcoma (sarcoma botryoides) of the urinary bladder of an infant. ( 13330015 )
1956
20
Myosarcoma of the heart in an infant. ( 13398888 )
1956
21
Retroperitoneal myosarcoma. ( 13250859 )
1955
22
Results of surgical treatment of 10 cases of myosarcoma of bladder. ( 13131441 )
1954
23
Myosarcoma of trachea associated with Riedel struma. ( 13007252 )
1953
24
Spontaneous regression of a case of myosarcoma. ( 13059772 )
1953
25
Myosarcoma of the urinary bladder. ( 13131419 )
1953
26
Myosarcoma of Meckel's diverticulum. ( 12984283 )
1952
27
An autopsy case of myosarcoma of the stomach. ( 12998907 )
1952
28
[Study on renal myosarcoma]. ( 13046331 )
1952
29
Myosarcoma of the bladder. ( 14825511 )
1951
30
Primary myosarcoma of the lung. ( 14853149 )
1951
31
On the myosarcoma experimentally produced with p-toluylenediamine in the rat (preliminary report). ( 14906602 )
1951
32
Myosarcoma of the urinary gladder; preliminary report of a favorable case. ( 15407581 )
1949
33
Subpectoral Sarcoma: ? Lymphosarcoma ? Myosarcoma. ( 19990813 )
1936
34
Subpectoral Sarcoma: ? Lymphosarcoma ? Myosarcoma. ( 20915210 )
1936
35
Leio-myosarcoma arising in a Fibromyoma. ( 19985774 )
1927
36
Case of Myosarcoma of Epididymis. ( 19983416 )
1923
37
Rhabdo-myosarcoma of the Uterus. ( 19976107 )
1912

Variations for Muscle Cancer

Expression for Muscle Cancer

Search GEO for disease gene expression data for Muscle Cancer.

Pathways for Muscle Cancer

GO Terms for Muscle Cancer

Cellular components related to Muscle Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 ASPSCR1 CREB3L2 DES EWSR1 FOXO1 MDM2
2 nucleoplasm GO:0005654 9.36 ASPSCR1 CREB3L2 FOXO1 MDM2 MYOD1 MYOG

Biological processes related to Muscle Cancer according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 transcription by RNA polymerase II GO:0006366 9.91 CREB3L2 MYOD1 PAX3 TFE3 TP53 WT1
2 negative regulation of apoptotic process GO:0043066 9.88 FOXO1 KIT MDM2 PAX7 TP53 WT1
3 positive regulation of transcription, DNA-templated GO:0045893 9.76 CREB3L2 FOXO1 MYOD1 MYOG PAX3 TFE3
4 positive regulation of gene expression GO:0010628 9.73 CD34 CREB3L2 KIT MDM2 TP53 WT1
5 regulation of transcription, DNA-templated GO:0006355 9.7 CREB3L2 EWSR1 FOXO1 MYOD1 MYOG PAX3
6 skeletal muscle tissue development GO:0007519 9.63 MYOD1 MYOG PAX7
7 muscle organ development GO:0007517 9.62 MYOD1 MYOG PAX3 PAX7
8 myotube differentiation GO:0014902 9.52 MYOD1 MYOG
9 positive regulation of skeletal muscle fiber development GO:0048743 9.51 MYOD1 MYOG
10 paracrine signaling GO:0038001 9.49 CD34 PGR
11 muscle cell fate commitment GO:0042693 9.48 MYOD1 MYOG
12 cellular response to actinomycin D GO:0072717 9.37 MDM2 TP53
13 positive regulation of transcription by RNA polymerase II GO:0045944 9.32 CREB3L2 FOXO1 MYOD1 MYOG PAX3 PAX7

Molecular functions related to Muscle Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 proximal promoter DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001077 9.8 CREB3L2 MYOG PGR TFE3 WT1
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.8 CREB3L2 MYOD1 MYOG PGR TFE3 TP53
3 sequence-specific DNA binding GO:0043565 9.8 FOXO1 MYOD1 MYOG PAX3 PAX7 PGR
4 ubiquitin protein ligase binding GO:0031625 9.76 FOXO1 MDM2 MYOD1 TP53
5 transcription regulatory region DNA binding GO:0044212 9.73 CREB3L2 TFE3 TP53 WT1
6 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.65 CREB3L2 FOXO1 MYOD1 MYOG PAX3 PAX7
7 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.55 CREB3L2 MYOD1 MYOG TP53 WT1
8 DNA-binding transcription factor activity GO:0003700 9.32 CREB3L2 FOXO1 MYOD1 MYOG PAX3 PAX7
9 DNA binding GO:0003677 10.07 CREB3L2 FOXO1 MYOD1 MYOG PAX3 PAX7

Sources for Muscle Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....